Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutation...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wen Dong, Pengfei Lei, Xin Liu, Qin Li, Xiangyang Cheng
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	lung cancer EML4-ALK nivolumab complete remission PD-L1 Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/c47edd3d89c54a13a5741f48b45b0d71
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c47edd3d89c54a13a5741f48b45b0d71
record_format	dspace
spelling	oai:doaj.org-article:c47edd3d89c54a13a5741f48b45b0d712021-11-04T07:08:29ZCase Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma1664-322410.3389/fimmu.2021.686057https://doaj.org/article/c47edd3d89c54a13a5741f48b45b0d712021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.686057/fullhttps://doaj.org/toc/1664-3224Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement.Wen DongPengfei LeiXin LiuQin LiXiangyang ChengFrontiers Media S.A.articlelung cancerEML4-ALKnivolumabcomplete remissionPD-L1Immunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung cancer EML4-ALK nivolumab complete remission PD-L1 Immunologic diseases. Allergy RC581-607
spellingShingle	lung cancer EML4-ALK nivolumab complete remission PD-L1 Immunologic diseases. Allergy RC581-607 Wen Dong Pengfei Lei Xin Liu Qin Li Xiangyang Cheng Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
description	Multiple gene-driven programmed cell death 1 ligand 1 (PD-L1)-expressing non-small-cell lung cancer (NSCLC) is very rare. Previous studies have shown that patients with NSCLC with anaplastic lymphoma kinase (ALK) gene rearrangement rarely benefit from PD-L1 inhibitors. Besides the secondary mutations in ALK gene, other mechanisms might contribute to tumor resistance to ALK tyrosine kinase inhibitors (ALK-TKIs). Herein, we present a case of PD-L1-overexpressing lung adenocarcinoma that harbors both EML4-ALK gene rearrangement and BRAF mutation. In particular, a second molecular analysis after resistance to first- and second-generation ALK-TKIs revealed a high PD-L1 expression and tumor mutation burden. Therefore, treatment with nivolumab monotherapy, an anti-PD-1 inhibitor, was started and the patient achieved complete remission. This case report suggested that PD-1 inhibitors might be an effective treatment option for patients with multiple gene-driven PD-L1-expressing NSCLC harboring ALK gene rearrangement.
format	article
author	Wen Dong Pengfei Lei Xin Liu Qin Li Xiangyang Cheng
author_facet	Wen Dong Pengfei Lei Xin Liu Qin Li Xiangyang Cheng
author_sort	Wen Dong
title	Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_short	Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_full	Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_fullStr	Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_full_unstemmed	Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma
title_sort	case report: complete response to nivolumab in a patient with programmed cell death 1 ligand 1-positive and multiple gene-driven anaplastic lymphoma kinase tyrosine kinase inhibitor-resistant lung adenocarcinoma
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c47edd3d89c54a13a5741f48b45b0d71
work_keys_str_mv	AT wendong casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma AT pengfeilei casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma AT xinliu casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma AT qinli casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma AT xiangyangcheng casereportcompleteresponsetonivolumabinapatientwithprogrammedcelldeath1ligand1positiveandmultiplegenedrivenanaplasticlymphomakinasetyrosinekinaseinhibitorresistantlungadenocarcinoma
_version_	1718445048474894336

Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma

Ejemplares similares